-
IRB professionals responding to IRB Advisor's 2008 Salary Survey continue to report modest salary increases and larger staffs over the previous year. But they worry that raises aren't keeping up with increasing workloads and that they and their staffs are burning out.
-
It's the little details that matter in the informed consent process.
-
More meaningfully involving communities especially minorities and other ethnic groups in clinical research isn't just good ethics it could help address under-recruitment and failure of cancer clinical trials, says one of the authors of a new report on the subject.
-
IRBs have an important role to play in improving community involvement in cancer clinical trials everything from increasing their own community membership to working with community advisory boards and pushing for more community-friendly informed consent.
-
The activities of state public health departments including disease tracking, cancer registries and death statistics can be a rich source of data for research.
-
Put any group of IRB administrators into the same room and soon you'll hear a discussion about how they have to deal with so many poorly-written protocols.
-
Clinical trial professionals and investigators should reconsider the inclusion/exclusion criteria and other factors to meet the needs of their study participants, an expert suggests.
-
Knowing that an investigator has a financial interest in a clinical trial doesn't substantially affect people's willingness to participate, according to a study that surveyed 470 people about their reaction to informed consent documents that detailed such interests.
-
A recent study of an instrument for assessing decisional capacity in patients with Alzheimer's disease shows that it's a reliable tool for determining whether those patients are competent to give their own consent for research.
-
The new IRB Advisor pilot program at Rutgers, The State University of New Jersey in New Brunswick, NJ, resulted in a reduction in protocol submissions that had to be returned to investigators, according to the IRB director.
